Gemcitabine plus cisplatin for the treatment of anthracycine-resistant advanced breast cancer
- VernacularTitle:吉西他滨联合顺铂治疗50例蒽环类耐药性晚期乳腺癌
- Author:
Binghe XU
;
Kai LI
;
Duanqi LIU
- Publication Type:Journal Article
- Keywords:
breast neoplasmas;
gemcitabine;
cisplatin
- From:China Oncology
2000;0(06):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose:To evaluate the efficacy and safety of combination chemotherapy of gemcitabine(GEM) and cisplatin(DDP) for anthracycine(ANT)-resistant advanced breast cancer(ABC). (GEM 1 200 mg/m 2 on day1 and 8,DDP 30mg/m 2 on day 3 to 5 in cycles of 21 days) Methods:From January 2000 to April 2003,fifty patients with ANT-resistant ABC were treated with combination chemotherapy of GEM and DDP. The median number of cycles was 3(range 2-4). Results:The overall response rate was 42.6%,The median time to progression was 4.5 months. The main side effect included gastrointestinal and hematologic toxicities,related grade 3 to 4 clinical adverse effect was nausea and vomiting in 12 cases (24%),anemia in 2 cases (4), leukopenia in 7 cases (14%),neutropenia in 4 cases (8%) and thrombocytopenia in 16 cases (32%).Conclusions:GEM and DDP combination is active in ANT-resistant ABC with an acceptable toxicity pattern and may well represent an interesting therapeutic choice after ANT regimen.
